Abstract
This study was intended to identify the genes responsible for ESBL- and carbapenemase-producing bacterial isolates obtained from Jizan region. A hospital-based cross-sectional study was conducted over a period of 3 months (15th November 2018–15th February 2019). Fifty non-duplicate, 3rd-generation cephalosporin and carbapenem-resistant isolates were collected from microbiology lab of a tertiary care hospital in Jizan province and were screened for ESBLs and MBLs by phenotypic methods (CDT). The positive isolates (by phenotypic method) were then scanned for the presence of blaESBLs and blaNDM-1 genes, respectively, by PCR.As a result, 10% isolates showed imipenem-cephalosporin co-resistance whereas 92% (46/50) of isolates were found to be ESBL producers by CDT. The maximum occurrence was observed for blaCTX-M (70%), followed by blaSHV (16%) and least occurrence was noted for blaTEM (12%). Moreover, 97% isolates (34/35) were of blaCTX-MGroup1 but one isolate showed the presence of blaCTX-M Group26. Despite the co-resistance of cephalosporin and carbapenem, 14% (7/50) were found to be MBL producer on phenotypic detection by Combination Disc Test (CDT), whereas all the isolates were found to be negative for blaNDM-1. Hence blaCTX-MGroup1 is present in quite high fraction followed by blaSHV in the bacterial isolates of Jizan region. Moreover, the occurrence of blaCTX-M Group1 and blaCTX-M Group26 in clinical isolates from the Jizan region of Saudi Arabia has been reported for the first time.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.